Mikael Elofsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3937088/publications.pdf

Version: 2024-02-01

123	5,530	109137	88477
papers	citations	35 h-index	70 g-index

133	133	133	5469
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10403-10408.	3.3	881
2	The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits Ikappa B kinase. Chemistry and Biology, 2001, 8, 759-766.	6.2	456
3	Targeting Bacterial Virulence. Chemistry and Biology, 2003, 10, 241-249.	6.2	206
4	Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2283-2288.	1.0	197
5	Small-Molecule Inhibitors Specifically Targeting Type III Secretion. Infection and Immunity, 2005, 73, 3104-3114.	1.0	197
6	A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14566-14571.	3.3	181
7	Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α', β'-epoxyketones. Chemistry and Biology, 1999, 6, 811-822.	6.2	141
8	Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. Journal of Internal Medicine, 2008, 264, 17-29.	2.7	133
9	Inhibition of Type III Secretion in Salmonella enterica Serovar Typhimurium by Small-Molecule Inhibitors. Antimicrobial Agents and Chemotherapy, 2007, 51, 2631-2635.	1.4	129
10	Derivatization Procedures for Reducing Oligosaccharides, Part 3: Preparation of Oligosaccharide Glycosylamines, and Their Conversion Into Glycosaccharide - Acrylamide Copolymers. Journal of Carbohydrate Chemistry, 1989, 8, 597-611.	0.4	119
11	Salicylidene Acylhydrazides That Affect Type III Protein Secretion in Salmonella enterica Serovar Typhimurium. Antimicrobial Agents and Chemotherapy, 2007, 51, 2867-2876.	1.4	105
12	Preparation of building blocks for glycopeptide synthesis by glycosylation of Fmoc amino acids having unprotected carboxyl groups. Tetrahedron, 1995, 51, 5643-5656.	1.0	97
13	Small molecule inhibitors of type III secretion inYersiniablock theChlamydia pneumoniaeinfection cycle. FEBS Letters, 2007, 581, 587-595.	1.3	94
14	Identification of Bacterial Target Proteins for the Salicylidene Acylhydrazide Class of Virulence-blocking Compounds. Journal of Biological Chemistry, 2011, 286, 29922-29931.	1.6	94
15	Building blocks for glycopeptide synthesis: glycosylation of 3-mercaptopropionic acid and Fmoc amino acids with unprotected carboxyl groups. Tetrahedron Letters, 1991, 32, 7613-7616.	0.7	91
16	Preparation of Tn and sialyl Tn building blocks used in Fmoc solid-phase synthesis of glycopeptide fragments from HIV gp120. Tetrahedron, 1997, 53, 369-390.	1.0	77
17	Removal of Acyl Protective Groups from Glycopeptides:Â Base Does Not Epimerize Peptide Stereocenters, and β-Elimination Is Slow. Journal of Organic Chemistry, 1996, 61, 560-565.	1.7	74
18	Reversal of the Antichlamydial Activity of Putative Type III Secretion Inhibitors by Iron. Infection and Immunity, 2007, 75, 3478-3489.	1.0	71

#	Article	IF	Citations
19	The Resveratrol Tetramer (-)-Hopeaphenol Inhibits Type III Secretion in the Gram-Negative Pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa. PLoS ONE, 2013, 8, e81969.	1.1	69
20	Design, Synthesis, and Multivariate Quantitative Structureâ^'Activity Relationship of SalicylanilidesPotent Inhibitors of Type III Secretion in Yersinia. Journal of Medicinal Chemistry, 2007, 50, 6177-6188.	2.9	66
21	Characterization of the Effects of Salicylidene Acylhydrazide Compounds on Type III Secretion in Escherichia coli O157:H7. Infection and Immunity, 2009, 77, 4209-4220.	1.0	63
22	Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia. Bioorganic and Medicinal Chemistry, 2010, 18, 2686-2703.	1.4	63
23	Derivatives of 8-hydroxyquinolineâ€"antibacterial agents that target intra- and extracellular Gram-negative pathogens. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3550-3553.	1.0	57
24	Inhibitory Activity of the Isoflavone Biochanin A on Intracellular Bacteria of Genus Chlamydia and Initial Development of a Buccal Formulation. PLoS ONE, 2014, 9, e115115.	1.1	54
25	Solid-Phase Synthesis of Glycopeptides: Immunological Studies with T Cell Stimulating Glycopeptides. Current Medicinal Chemistry, 1997, 4, 85-116.	1.2	54
26	Pseudoceramines Aâ€"D, new antibacterial bromotyrosine alkaloids from the marine sponge Pseudoceratina sp.. Organic and Biomolecular Chemistry, 2011, 9, 6755.	1.5	49
27	PARP Inhibitor with Selectivity Toward ADP-Ribosyltransferase ARTD3/PARP3. ACS Chemical Biology, 2013, 8, 1698-1703.	1.6	48
28	Towards small molecule inhibitors of mono-ADP-ribosyltransferases. European Journal of Medicinal Chemistry, 2015, 95, 546-551.	2.6	46
29	Mutations in hemG Mediate Resistance to Salicylidene Acylhydrazides, Demonstrating a Novel Link between Protoporphyrinogen Oxidase (HemG) and Chlamydia trachomatis Infectivity. Journal of Bacteriology, 2013, 195, 4221-4230.	1.0	41
30	Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion. Journal of Antibiotics, 2012, 65, 397-404.	1.0	39
31	Protection of Mice From a Chlamydia trachomatis Vaginal Infection Using a Salicylidene Acylhydrazide, a Potential Microbicide. Journal of Infectious Diseases, 2011, 204, 1313-1320.	1.9	38
32	N -Acylated Derivatives of Sulfamethoxazole and Sulfafurazole Inhibit Intracellular Growth of Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy, 2014, 58, 2968-2971.	1.4	38
33	Discovery of Ligands for ADP-Ribosyltransferases via Docking-Based Virtual Screening. Journal of Medicinal Chemistry, 2012, 55, 7706-7718.	2.9	37
34	14-3-3 proteins activate Pseudomonas exotoxins-S and -T by chaperoning a hydrophobic surface. Nature Communications, 2018, 9, 3785.	5.8	37
35	A Potent Trivalent Sialic Acid Inhibitor of Adenovirus Type 37 Infection of Human Corneal Cells. Angewandte Chemie - International Edition, 2011, 50, 6519-6521.	7.2	36
36	Monitoring Solid-Phase Glycoside Synthesis with19F NMR Spectroscopy. Organic Letters, 2001, 3, 1463-1466.	2.4	35

#	Article	IF	Citations
37	Multivalent sialic acid conjugates inhibit adenovirus type 37 from binding to and infecting human corneal epithelial cells. Antiviral Research, 2007, 73, 92-100.	1.9	35
38	Solid-Phase Synthesis of Î±-Gal Epitopes:Â On-Resin Analysis of Solid-Phase Oligosaccharide Synthesis with19F NMR Spectroscopy. Journal of Organic Chemistry, 2003, 68, 7281-7288.	1.7	34
39	Total Synthesis of the Resveratrol Oligomers (Â±)â€Ampelopsin B and (Â±)â€Ïµâ€Viniferin. European Journal of Organic Chemistry, 2016, 2016, 426-429.	1.2	34
40	Natural product inspired library synthesis - Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. European Journal of Medicinal Chemistry, 2018, 143, 1077-1089.	2.6	34
41	Multivalent HSA Conjugates of 3â€²-Sialyllactose are Potent Inhibitors of Adenoviral Cell Attachment and Infection. ChemBioChem, 2005, 6, 358-364.	1.3	33
42	Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. International Journal of Antimicrobial Agents, 2010, 36, 145-150.	1.1	32
43	Solid-phase synthesis and conformational studies of glycosylated derivatives of helper-T-cell immunogenic peptides from hen-egg lysozyme. Carbohydrate Research, 1993, 246, 89-103.	1.1	31
44	Triazole linker-based trivalent sialic acid inhibitors of adenovirus type 37 infection of human corneal epithelial cells. Organic and Biomolecular Chemistry, 2015, 13, 9194-9205.	1.5	31
45	Total Synthesis of Viniferifuran, Resveratrolâ€Piceatannol Hybrid, Anigopreissin A and Analogues â€“ Investigation of Demethylation Strategies. Advanced Synthesis and Catalysis, 2016, 358, 4085-4092.	2.1	31
46	Diversity-Oriented Synthesis of Libraries Based on Benzofuran and 2,3-Dihydrobenzofuran Scaffolds. ACS Combinatorial Science, 2017, 19, 370-376.	3.8	31
47	Type III secretion inhibitors for the management of bacterial plant diseases. Molecular Plant Pathology, 2019, 20, 20-32.	2.0	31
48	Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis. Journal of Antibiotics, 2015, 68, 609-614.	1.0	30
49	Design of a Generalâ€Purpose European Compound Screening Library for EUâ€OPENSCREEN. ChemMedChem, 2014, 9, 2309-2326.	1.6	29
50	Benzylidene Acylhydrazides Inhibit Chlamydial Growth in a Type III Secretion- and Iron Chelation-Independent Manner. Journal of Bacteriology, 2014, 196, 2989-3001.	1.0	29
51	Salicylanilides are Potent Inhibitors of Type III Secretion in Yersinia. , 2003, 529, 97-100.		28
52	Sialic Acid-Containing Glycans as Cellular Receptors for Ocular Human Adenoviruses: Implications for Tropism and Treatment. Viruses, 2019, 11, 395.	1.5	28
53	Inhibitors of type III secretion in Yersinia: Design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorganic and Medicinal Chemistry, 2007, 15, 6994-7011.	1.4	26
54	Isolation and Characterization of Anti-Adenoviral Secondary Metabolites from Marine Actinobacteria. Marine Drugs, 2014, 12, 799-821.	2.2	25

#	Article	IF	Citations
55	Synthesis, Biological Evaluation, and Structureâ€“Activity Relationships of 2-[2-(Benzoylamino)benzoylamino]benzoic Acid Analogues as Inhibitors of Adenovirus Replication. Journal of Medicinal Chemistry, 2012, 55, 3170-3181.	2.9	24
56	[11] Direct synthesis of glycosylated amino acids from carbohydrate peracetates and Fmoc amino acids: Solid-phase synthesis of biomedicinally interesting glycopeptides. Methods in Enzymology, 1997, 289, 221-245.	0.4	23
57	The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo. Journal of Antibiotics, 2017, 70, 937-943.	1.0	23
58	Identification of Poly(ADP-Ribose) Polymerase Macrodomain Inhibitors Using an AlphaScreen Protocol. SLAS Discovery, 2018, 23, 353-362.	1.4	23
59	PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers. Cell Death and Differentiation, 2019, 26, 1615-1630.	5.0	23
60	Attenuation of Pseudomonas aeruginosa infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis. Virulence, 2020, 11, 795-804.	1.8	23
61	Small-Molecule Screening Using a Whole-Cell Viral Replication Reporter Gene Assay Identifies 2-{[2-(Benzoylamino)Benzoyl]Amino}-Benzoic Acid as a Novel Antiadenoviral Compound. Antimicrobial Agents and Chemotherapy, 2010, 54, 3871-3877.	1.4	22
62	Building blocks for glycopeptide synthesis: Preparation of Î±-O-fucosylated fmoc serine and threonine in one step from L-fucose tetraacetate. Tetrahedron Letters, 1996, 37, 7645-7648.	0.7	21
63	The gallium(III)â€“salicylidene acylhydrazide complex shows synergistic anti-biofilm effect and inhibits toxin production by Pseudomonas aeruginosa. Journal of Inorganic Biochemistry, 2014, 138, 1-8.	1.5	20
64	Synthesis of Tn and sialyl Tn building blocks for solid phase glycopeptide synthesis. Tetrahedron Letters, 1995, 36, 7499-7502.	0.7	19
65	Fluorinated Protective Groups for On-Resin Quantification of Solid-Phase Oligosaccharide Synthesis with19F NMR Spectroscopy. ChemBioChem, 2002, 3, 1266-1269.	1.3	18
66	Gel-phase19F NMR spectral quality for resins commonly used in solid-phase organic synthesis; a study of peptide solid-phase glycosylations. Organic and Biomolecular Chemistry, 2004, 2, 1770-1776.	1.5	18
67	A Fluorinated Selenide Linker for Solid-Phase Synthesis ofn-Pentenyl Glycosides. Organic Letters, 2004, 6, 4885-4888.	2.4	18
68	Statistical Molecular Design of Balanced Compound Libraries for QSAR Modeling. Current Medicinal Chemistry, 2010, 17, 2001-2016.	1.2	18
69	Design, synthesis and evaluation of novel polypharmacological antichlamydial agents. European Journal of Medicinal Chemistry, 2015, 101, 595-603.	2.6	18
70	Formation of lactones from sialylated MUC1 glycopeptides. Organic and Biomolecular Chemistry, 2006, 4, 713.	1.5	17
71	Structural Characterisation of Tpx from Yersinia pseudotuberculosis Reveals Insights into the Binding of Salicylidene Acylhydrazide Compounds. PLoS ONE, 2012, 7, e32217.	1.1	17
72	Identification of a small molecule that stabilizes lipoprotein lipase in vitro and lowers triglycerides in vivo. Biochemical and Biophysical Research Communications, 2014, 450, 1063-1069.	1.0	17

#	Article	IF	Citations
73	Solving the Supply of Resveratrol Tetramers from Papua New Guinean Rainforest Anisoptera Species That Inhibit Bacterial Type III Secretion Systems. Journal of Natural Products, 2014, 77, 2633-2640.	1.5	16
74	Novel High-Throughput Screening Method for Identification of Fungal Dimorphism Blockers. Journal of Biomolecular Screening, 2015, 20, 285-291.	2.6	16
75	2-[4,5-Difluoro-2-(2-Fluorobenzoylamino)-Benzoylamino]Benzoic Acid, an Antiviral Compound with Activity against Acyclovir-Resistant Isolates of Herpes Simplex Virus Types 1 and 2. Antimicrobial Agents and Chemotherapy, 2012, 56, 5735-5743.	1.4	15
76	Mycobacterium tuberculosis virulence inhibitors discovered by Mycobacterium marinum high-throughput screening. Scientific Reports, 2019, 9, 26.	1.6	15
77	Exploring resveratrol dimers as virulence blocking agents â€“ Attenuation of type III secretion in Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Scientific Reports, 2020, 10, 2103.	1.6	15
78	Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. Scientific Reports, 2018, 8, 1925.	1.6	14
79	Structureâ€“activity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity. European Journal of Medicinal Chemistry, 2018, 143, 568-576.	2.6	14
80	Screening for Inhibition of Vibrio cholerae VipA-VipB Interaction Identifies Small-Molecule Compounds Active against Type VI Secretion. Antimicrobial Agents and Chemotherapy, 2014, 58, 4123-4130.	1.4	13
81	Synthesis of Indole-, Benzo[b]thiophene-, and Benzo[b]selenophene-Based Analogues of the Resveratrol Dimers Viniferifuran and (Â±)-Dehydroampelopsin B. Organic Letters, 2018, 20, 6650-6654.	2.4	13
82	Syntheses of pseudoceramines Aâ€“D and a new synthesis of spermatinamine, bromotyrosine natural products from marine sponges. Organic and Biomolecular Chemistry, 2012, 10, 1246-1254.	1.5	12
83	Identification of Inhibitors of Pseudomonas aeruginosa Exotoxin-S ADP-Ribosyltransferase Activity. Journal of Biomolecular Screening, 2016, 21, 590-595.	2.6	12
84	Pentavalent Sialic Acid Conjugates Block Coxsackievirus A24 Variant and Human Adenovirus Type 37â€“Viruses That Cause Highly Contagious Eye Infections. ACS Chemical Biology, 2020, 15, 2683-2691.	1.6	12
85	Preparation and structural characterization of N-glycated amino acid and linear or cyclic dipeptides containing the 6-amino-6-deoxy-1,2:3,4-di-O-isopropylidene-Î±-d-galactopyranose moiety. Carbohydrate Research, 1996, 287, 1-19.	1.1	11
86	Solid-phase synthesis of serine-based glycosphingolipid analogues for preparation of glycoconjugate arrays. Organic and Biomolecular Chemistry, 2005, 3, 309.	1.5	11
87	N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	11
88	Characterization of a Novel Mammalian Phosphatase Having Sequence Similarity toSchizosaccharomyces pombePHO2 andSaccharomyces cerevisiaePHO13â€. Biochemistry, 2002, 41, 7841-7848.	1.2	10
89	Design, Synthesis, and Evaluation of N-Acyl Modified Sialic Acids as Inhibitors of Adenoviruses Causing Epidemic Keratoconjunctivitis. Journal of Medicinal Chemistry, 2009, 52, 3666-3678.	2.9	10
90	Antiviral Activity of Benzavir-2 against Emerging Flaviviruses. Viruses, 2020, 12, 351.	1.5	10

#	Article	IF	Citations
91	Chemical Probes to Study ADP-Ribosylation: Synthesis and Biochemical Evaluation of Inhibitors of the Human ADP-Ribosyltransferase ARTD3/PARP3. Journal of Medicinal Chemistry, 2013, 56, 9556-9568.	2.9	9
92	Structureâ€“activity relationships for lipoprotein lipase agonists that lower plasma triglycerides inÂvivo. European Journal of Medicinal Chemistry, 2015, 103, 191-209.	2.6	9
93	Synthesis of 4â€Formylâ€2â€arylbenzofuran Derivatives by PdCl(C₃H₅)dppbâ€Catalyzed Tandem Sonogashira Couplingâ€Cyclization under Microwave Irradiation â€•Application to the Synthesis of Viniferifuran Analogues. ChemistrySelect, 2017, 2, 6245-6248.	0.7	9
94	Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology, 2019, 9, 250.	1.8	9
95	Sialic Acid as a Biomarker Studied in Breast Cancer Cell Lines In Vitro Using Fluorescent Molecularly Imprinted Polymers. Applied Sciences (Switzerland), 2021, 11, 3256.	1.3	9
96	Synthesis of a water-soluble serine-based neoglycolipid which can be covalently linked to solid phases. Carbohydrate Research, 1994, 258, 123-133.	1.1	8
97	Loading of the Antigen-Presenting Protein CD1d with Synthetic Glycolipids. ChemBioChem, 2004, 5, 437-444.	1.3	8
98	Corticosteroids protect infected cells against mycobacterial killing inÂvitro. Biochemical and Biophysical Research Communications, 2019, 511, 117-121.	1.0	8
99	Synthesis and evaluation of 2-(2-fluoro-4-hydroxymethyl-5-methoxy-phenoxy)acetic acid as a linker in solid-phase synthesis monitored by gel-phase19F NMR spectroscopy. Organic and Biomolecular Chemistry, 2007, 5, 2464-2471.	1.5	7
100	Solidâ€phase synthesis and conformational studies of helper T cell immunogenic peptides that carry carbohydrate haptens linked to serine. International Journal of Peptide and Protein Research, 1996, 47, 340-347.	0.1	7
101	Synthesis of 2-(2-Aminopyrimidine)-2,2-difluoroethanols as Potential Bioisosters of Salicylidene Acylhydrazides. Molecules, 2010, 15, 4423-4438.	1.7	7
102	Fluorescent Molecularly Imprinted Polymer Layers against Sialic Acid on Silica-Coated Polystyrene Coresâ€”Assessment of the Binding Behavior to Cancer Cells. Cancers, 2022, 14, 1875.	1.7	7
103	Application of gel-phase19F NMR spectroscopy for optimization of solid-phase synthesis of a hydrophobic peptide from the signal sequence of the mucin MUC1. Journal of Peptide Science, 2007, 13, 354-361.	0.8	6
104	Carbamate Linker Strategy in Solidâ€Phase Synthesis of Aminoâ€Functionalized Glycoconjugates for Attachment to Solid Surfaces and Investigation of Proteinâ€Carbohydrate Interactions. European Journal of Organic Chemistry, 2009, 2009, 349-357.	1.2	6
105	Expression, purification, crystallization and initial X-ray diffraction analysis of thiol peroxidase fromYersinia pseudotuberculosis. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 1606-1609.	0.7	6
106	In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. International Journal of Antimicrobial Agents, 2012, 40, 354-360.	1.1	6
107	Identification of Small Molecules Blocking the Pseudomonas aeruginosa Type III Secretion System Protein PcrV. Biomolecules, 2021, 11, 55.	1.8	6
108	NMR Tube Filter Reactor for Solid-Phase Synthesis and Gel-Phase19F NMR Spectroscopy. ACS Combinatorial Science, 2006, 8, 150-152.	3.3	5

#	Article	IF	Citations
109	N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 513-521.	2.5	5
110	Synthesis of [4-(2-Hydroxyphenyl)thiazol-2-yl]methanones as Potential Bioisosteres of Salicylidene Acylhydrazides. Molecules, 2010, 15, 6019-6034.	1.7	4
111	Cyclopropylmethyl Protection of Phenols: Total Synthesis of the Resveratrol Dimers Anigopreissinâ€...A and Resveratrolâ€“Piceatannol Hybrid. ChemistryOpen, 2018, 7, 953-956.	0.9	4
112	Preliminary Pharmacokinetics of the Bacterial Virulence Inhibitor Nâ€²-(3,5-Dibromo-2-Hydroxy-Benzylidenene)-Nicotinic Acid Hydrazide. Advances in Experimental Medicine and Biology, 2012, 954, 349-356.	0.8	4
113	Small Molecule Screening for Inhibitors of the YopH Phosphatase of Yersinia pseudotuberculosis. Advances in Experimental Medicine and Biology, 2012, 954, 357-363.	0.8	3
114	Screening for Inhibitors of Acetaldehyde Dehydrogenase (AdhE) from Enterohemorrhagic Escherichia coli (EHEC). SLAS Discovery, 2018, 23, 815-822.	1.4	3
115	Red Fluorescent Chlamydia trachomatis Applied to Live Cell Imaging and Screening for Antibacterial Agents. Frontiers in Microbiology, 2018, 9, 3151.	1.5	3
116	Synthesis of 4-O-Alkylated N-Acetylneuraminic Acid Derivatives. Journal of Organic Chemistry, 2021, 86, 9145-9154.	1.7	3
117	Exploring the Effect of Structure-Based Scaffold Hopping on the Inhibition of Coxsackievirus A24v Transduction by Pentavalent N-Acetylneuraminic Acid Conjugates. International Journal of Molecular Sciences, 2021, 22, 8418.	1.8	2
118	Synthesis and application of Nâ€[1â€(4â€(4â€fluorophenyl)â€2,6â€dioxocyclohexylidene)ethyl](Fde)â€protected amino acids for optimization of solidâ€phase peptide synthesis using gelâ€phase ¹⁹F NMR spectroscopy. Journal of Peptide Science, 2009, 15, 264-271.	0.8	1
119	Synthesis and Application of a 2-[(4-Fluorophenyl)-sulfonyl]ethoxy Carbonyl(Fsec) Protected Glycosyl Donor in Carbohydrate Chemistry. Molecules, 2010, 15, 5708-5720.	1.7	1
120	Crystal structures of WrbA, a spurious target of the salicylidene acylhydrazide inhibitors of type III secretion in Gram-negative pathogens, and verification of improved specificity of next-generation compounds. Microbiology (United Kingdom), 2022, 168, .	0.7	1
121	Statistical Molecular Design: A Tool to Follow Up Hits from Small-Molecule Screening. Methods in Molecular Biology, 2014, 1056, 169-188.	0.4	0
122	A carbohydrate antigen linked to a T-cell immunogenic peptide induces T-cell clones selective for carbohydrate. , 1993, , 840-841.		0
123	Exploring divalent conjugates of 5-N-acetyl-neuraminic acid as inhibitors of coxsackievirus A24 variant (CVA24v) transduction. RSC Advances, 2022, 12, 2319-2331.	1.7	0